Expression of CDX2 in duodenal carcinoma and its relationship with prognosis
Objective To investigate the expression of caudal type homeobox transcription factor 2(CDX2)in duodenal carcinoma and its relationship with prognosis.Methods Clinical data and pathological sections of 61 patients with duodenal carcinoma confirmed by histopathology or cytology from November 2011 to December 2022 were collected.The expression of CDX2 was detected by immunohistochemistry.Kaplan-Meier method and Log-rank test were used for survival analysis.Cox proportional regression model was used for multivariate analysis.Results The positive rate of CDX2 in duodenal carcinoma was 78.7%(48/61).The positive rate of CDX2 expression in stageⅠ-Ⅱ patients was 89.7%,which was higher than 68.8%in stage Ⅲ-Ⅳ patients(P<0.05),but the expression of CDX2 was not correlated with gender,age,differentiation,CEA and anemia(P>0.05).Univariate analysis showed that CDX2 expression,differentiation,TNM stage and CEA were correlated with prognosis.The median OS of CDX2 negative and positive patients was 21.6 months and 49.8 months,respectively(P=0.015).The median OS was 13.0 months and 82.5 months,respectively,for low-differentiation and medium-high differentiation(P<0.001).The median OS for stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳpatients was 72.3 and 13.0 months,respectively(P<0.001).The median OS of CEA<5 μg/L and CEA≥5 μg/L were 49.8 months and 9.4 months,respectively(P=0.002).Age,sex and anemia were not associated with prognosis(P>0.05).Multivariate analysis showed that the expression of CDX2(RR=2.697,95%CI:1.191-6.106,P=0.017)was an independent prognostic factor of duodenal carcinoma.Conclusion CDX2 is an independent prognostic factor affecting duodenal cancer patients,and the prognosis of CDX2 positive patients is significantly better than that of CDX2 negative patients.
NETL
NSTL
万方数据
